Literature DB >> 6724515

Hepatocytes of Zones 1 and 3 conjugate sulfobromophthalein with glutathione.

E H Chen, J J Gumucio, N H Ho, D L Gumucio.   

Abstract

The capacity of hepatocytes of Zones 1 and 3 of the liver acinus to conjugate sulfobromophthalein (BSP) with glutathione and to secrete the conjugate into bile was studied. BSP was infused into the in situ perfused rat liver in concentrations of 0.01 and 0.05 mM. Perfusions were performed either in the portal to hepatic vein direction (forward perfusion) or in the hepatic vein to portal vein direction (retrograde perfusion). Hepatocytes contributing to the uptake, metabolism and biliary secretion of BSP were directly assessed qualitatively by light microscopy, and also semiquantitatively by microspectrophotometry. BSP was taken up predominantly by hepatocytes of Zone 1 during forward perfusion and by those of Zone 3 during the retrograde perfusion of BSP. The biliary products of BSP metabolism by each acinar zone were subsequently assessed. Hepatocytes of both Zones 1 and 3 of the acinus secreted BSP into bile in the form of BSP-glutathione, and BSP-glutathione conjugate represented about 78% of the total BSP secreted into bile by each zone. The rate of BSP biliary secretion by both zones was similar at a concentration of 0.01 mM BSP, while a slight decrease (15%) in BSP secretory rate by hepatocytes of zone 3 was observed at concentrations of BSP near biliary Tm. Liver perfusion with exogenous BSP-glutathione provided results similar to those obtained with BSP. In contrast, the perfusion of 3,6- dibromosulphthalein , a compound which is not conjugated by hepatocytes, resulted in similar biliary secretory rates regardless of the direction of perfusion. These results indicate that: (a) the capacity for glutathione conjugation of BSP is distributed among hepatocytes of all acinar zones; (b) near biliary Tm, the biliary secretory rate of BSP by hepatocytes of Zone 3 is slower than that of hepatocytes of zone 1, and (c) in vivo, all hepatocytes likely contribute to the uptake, metabolism and biliary secretion of BSP.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6724515     DOI: 10.1002/hep.1840040320

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

Review 1.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

2.  High zone-selectivity of cell permeabilization following digitonin-pulse perfusion of rat liver. A re-interpretation of the microcirculatory zones.

Authors:  B Quistorff; P Rømert
Journal:  Histochemistry       Date:  1989

Review 3.  Biochemistry of bile secretion.

Authors:  R Coleman
Journal:  Biochem J       Date:  1987-06-01       Impact factor: 3.857

4.  Effect of plasma protein binding on elimination of taurocholate by isolated perfused rat liver: comparison of venous equilibrium, undistributed and distributed sinusoidal, and dispersion models.

Authors:  R H Smallwood; D J Morgan; G W Mihaly; D B Jones; R A Smallwood
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

5.  Demonstration by in situ hybridization of the zonal modulation of rat liver cytochrome P-450b and P-450e gene expression after phenobarbital.

Authors:  E Wojcik; C Dvorak; J Chianale; P G Traber; D Keren; J J Gumucio
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

6.  Competing pathways in drug metabolism. II. An identical, anterior enzymic distribution for 2- and 5-sulfoconjugation and a posterior localization for 5-glucuronidation of gentisamide in the rat liver.

Authors:  M E Morris; V Yuen; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1988-12

7.  Acute and chronic changes in the microcirculation of the liver in inbred strains of mice following infection with mouse hepatitis virus type 3.

Authors:  P J MacPhee; V J Dindzans; L S Fung; G A Levy
Journal:  Hepatology       Date:  1985 Jul-Aug       Impact factor: 17.425

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.